Nuala A. Helsby
University of Auckland
New Zealand
Name/email consistency: high
- The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Helsby, N.A., Hui, C.Y., Goldthorpe, M.A., Coller, J.K., Soh, M.C., Gow, P.J., De Zoysa, J.Z., Tingle, M.D. Br. J. Clin. Pharmacol (2010)
- Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? Helsby, N.A., Lo, W.Y., Thompson, P., Laking, G.R. Cancer Chemother. Pharmacol. (2010)
- Is the prevalence of CYP2C19 genetic variants different in Pacific people than in New Zealand Europeans? Helsby, N., Goldthorpe, M., Gow, P., de Zoysa, J. N. Z. Med. J. (2010)
- Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease. Helsby, N.A. Proc. West. Pharmacol. Soc. (2008)
- Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugs. Helsby, N.A., Goldthorpe, M.A., Tang, M.H., Atwell, G.J., Smith, E.M., Wilson, W.R., Tingle, M.D. Drug Metab. Dispos. (2008)
- Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. Helsby, N.A., Atwell, G.J., Yang, S., Palmer, B.D., Anderson, R.F., Pullen, S.M., Ferry, D.M., Hogg, A., Wilson, W.R., Denny, W.A. J. Med. Chem. (2004)
- Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Helsby, N.A., Wheeler, S.J., Pruijn, F.B., Palmer, B.D., Yang, S., Denny, W.A., Wilson, W.R. Chem. Res. Toxicol. (2003)